Search
Fomivirsen
go.drugbank.com/drugs/DB06759ApprovedWithdrawnIt was discovered by scientists at the National Institutes of Health (NIH) and was first developed by _Isis Pharmaceuticals_ and subsequently licensed to _Novartis_ [A31990]. … The drug was withdrawn by the FDA because while there was a high unmet need for drugs to treat CMV when the drug was initially discovered and developed due to the CMV arising in people with AIDS, the development
Daclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnIt exerts its antiviral action by preventing RNA replication and virion assembly via binding to NS5A, a nonstructural phosphoprotein encoded by HCV. … Hepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells
go.drugbank.com/drugs/DB15731InvestigationalRegarding the modifications of these UC-MSCs, CD362, also known as syndecan-2, is a surface marker identified on MSCs with enhanced clonogenicity and immunomodulatory properties. … feature allows them to be hypoimmunogenic and non-inducible for tumorigenesis.
Nilutamide
go.drugbank.com/drugs/DB00665ApprovedInvestigationalNilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). … To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Categories: Antiandrogens, non-steroidalRibavirin
go.drugbank.com/drugs/DB00811ApprovedInvestigationalRibavirin is added to decrease relapse rates by accelerating viral clearance early in the treatment course [A19645]. … When used to treat Hepatitis C virus (HCV) infections, it is always used as a part of combination therapies as ribavirin monotherapy is not efficacious in the treatment of chronic hepatitis C infection
Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)Clascoterone
go.drugbank.com/drugs/DB12499ApprovedInvestigational[A218771] By competing with androgens for binding to androgen receptors, clascoterone works by blocking the androgen receptor signalling cascades that promote acne pathogenesis, such as sebaceous gland … It binds to androgen receptors with high affinity.
Boceprevir
go.drugbank.com/drugs/DB08873ApprovedWithdrawnVictrelis is no longer widely used as interferon-free therapies have been developed. … Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Tofersen
go.drugbank.com/drugs/DB14782ApprovedInvestigational[A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation. … [L46133] In June of 2024, it was additionally approved by the EMA for the same indication.
Synonyms: -(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R, DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SPDextroamphetamine
go.drugbank.com/drugs/DB01576ApprovedIllicitInvestigationalDextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCabotegravir
go.drugbank.com/drugs/DB11751ApprovedInvestigationalCabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, [rilpivirine]. … [A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals.